

Leica HER2 FISH System - 30 Test Instructions For Use

For use on Leica Biosystems' BOND-MAX and BOND-III System.

TA9217 is a fluorescence *in situ* hybridization product designed to stain 30 tests (30 slides stained with LSI HER2/CEP17 Dual Probe).



Leica Biosystems Newcastle Ltd
Balliol Business Park West
Benton Lane
Newcastle Upon Tyne NE12 8EW
United Kingdom
☎ +44 191 215 4242



Leica Biosystems Canada
71 Four Valley Drive
Concord, Ontario L4K 4V8
Canada
☎ +1 800 248 0123

Leica Biosystems Inc
1700 Leider Lane
Buffalo Grove IL 60089
USA
☎ +1 800 248 0123

Leica Biosystems Melbourne
Pty Ltd
495 Blackburn Road
Mt Waverly VIC 3149
Australia
☎ +61 2 8870 3500

Contents

Intended Use	3
For <i>in vitro</i> diagnostic use	3
Required training	3
Summary and Explanation	3
Background	3
Clinical Concordance Summary BOND-MAX System	4
Clinical Concordance Summary BOND-III System	4
Principle of Procedure	5
Components Provided	5
Directions For Use	5
Storage and Stability	5
Specimen Preparation	5
Warnings and Precautions	6
Procedure	6
A. Reagents required but not supplied	6
B. Equipment required but not supplied	6
C. Methodology	7
D. Bond Enzyme Pretreatment	7
E. Default Staining Protocol	7
F. Procedure Steps	7
G. Slide Storage	8
Signal Assessment and Enumeration	9
Recommended Method for LSI HER2 to CEP17 Ratio Determination	10
Leica HER2 FISH System - 30 Test Interpretation Guide	11
Sample Score Sheet	12
Quality Control	13
Limitations	13
A. General Limitations	13
B. Product Specific Limitations	14
Clinical Concordance of Leica HER2 FISH System - 30 Test to Abbott Molecular PathVysion HER-2 DNA Probe Kit - Breast	14
2x2 Concordance Results BOND-MAX System - Breast	15
2x2 Concordance Results BOND-III System - Breast	16
Clinical Concordance of Leica HER2 FISH System - 30 Test to Abbott Molecular PathVysion HER-2 DNA Probe Kit - Gastric	17
2x2 Concordance Results BOND-MAX System - Gastric	17
Precision Testing – BOND-MAX System	18
A. Within Run Precision Study	18
B. Within Instrument Precision Study	18
C. Between Run Precision Study	18
D. Between Laboratory Precision Study	18
E. Between Observer Precision Study	18
F. Lot-to-Lot Precision Study	19
Precision Testing – BOND-III System	19
G. Within Run Precision Study	19
H. Within Instrument Precision Study	19
I. Between Run Precision Study	19
J. Between Laboratory Precision Study	19
K. Between Observer Precision Study	20
L. Lot-to-Lot Precision Study	20
Assay Robustness	20
Troubleshooting	22
References	24
License Agreement	25

Intended Use

For *in vitro* diagnostic use

The Leica HER2 FISH System - 30 Test is designed to detect amplification of the HER2/neu gene via fluorescence *in situ* hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer and adenocarcinomas of the stomach (including gastroesophageal junction) tissue specimens. The Leica HER2 FISH System - 30 Test is indicated as an aid in the assessment of patients for whom Herceptin® (trastuzumab) treatment is being considered (see Herceptin package insert). The Leica HER2 FISH System - 30 Test is not intended for use to screen for or diagnose breast cancer. All other available clinical information should also be taken into consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. No treatment decision for breast cancer patients should be based on HER2 gene amplification status alone.

Note: All of the patients in the Herceptin clinical trials were selected using an investigational immunocytochemical Clinical Trial Assay (CTA). None of the patients in those trials were selected using the Leica HER2 FISH System - 30 Test. The Leica HER2 FISH System - 30 Test has been compared to the Abbott Molecular PathVysion® HER-2 DNA Probe Kit assay on an independent set of samples and found to provide acceptably concordant results, as indicated in the Clinical Concordance Summary. The actual correlation of the results of the Leica HER2 FISH System - 30 Test to clinical outcome has not been established.

All of the patients in the Herceptin® advanced gastric cancer (ToGA) clinical trials were selected using the Dako HercepTest. None of the patients in those trials were selected using the Leica HER2 FISH System - 30 Test. The Leica HER2 FISH System - 30 Test has been compared to the Abbott Molecular PathVysion® HER-2 DNA Probe Kit assay on an independent set of samples and found to provide acceptably concordant results, as indicated in the Clinical Concordance Summary. The actual correlation of the results of the Leica HER2 FISH System - 30 Test to clinical outcome has not been established.

** Herceptin® is a trademark of Genentech, Inc. and F. Hoffmann-La Roche Ltd. PathVysion® is a trademark of Abbott Molecular Inc. All Rights Reserved. Used under License.*

Required training

Leica Biosystems will provide training in specimen preparation, assay procedure, and interpretation of FISH testing of the HER2 gene for all users.

Summary and Explanation

Background

The HER2 gene, alternatively known as neu or c-erbB2, is located on the long arm of chromosome 17 at position 17q11-12 (1). Both the HER2 gene and its 185 kD encoded protein have been shown to play a major role in malignant transformation and tumor progression of breast cancer (2).

HER2 functions as a prognostic marker, with gene amplification and protein over expression being linked to an increased rate of disease recurrence and higher mortality. HER2 also functions as a predictive marker for selected systemic chemotherapy and targeted treatments (3). Specifically, amplification of the HER2 gene has been shown to be an indicator of poor prognosis in node-positive breast cancer (4-8). Furthermore, one study indicates the prognostic value of HER2 to be stronger among patients treated with chemotherapy (7). However, in predicting disease-free and overall survival in individual patients, other established prognostic factors such as tumor size, number of positive lymph nodes and steroid receptor status must also be taken into consideration.

Overexpression of the HER2 oncoprotein, as a result of gene amplification found in breast cancer cells, suggests HER2 as a target for an antibody-based therapy (3) - while results from the ToGA trial clearly indicate that the use of Herceptin® in gastric cancer along with chemotherapy is an effective treatment which improves overall survival in HER2 positive gastric cancers (9). Herceptin (trastuzumab), a humanized monoclonal antibody (10) that binds with

high affinity to the HER2 oncoprotein has been shown to inhibit the proliferation of human tumor cells that overexpress HER2 oncoprotein both *in vitro* and *in vivo* (11-13). Since the development of Herceptin, the detection of both the HER2 gene and protein have become essential tools in the assessment of breast tumors, directing both therapy selection and subsequent patient management (14,15).

In both interphase and metaphase cells derived from human breast carcinoma cell lines, FISH has been used to show HER2 gene amplification (16-19). For quantification of HER2 gene amplification, FISH assesses the level of HER2 gene amplification directly in the tumor cells. The characteristic morphology of the tissue and the spatial distribution of oncogene copies in individual uncultured primary breast carcinomas are retained. Aberrations in chromosome 17 copy number (aneusomy) are also commonly found in breast tumors. These may present as chromosome deletions or gains (polysomy). This chromosomal variation has critical impact on the interpretation and reporting of HER2 gene amplification status. Therefore, measurement of chromosome 17 copy number in conjunction with HER2 is critically important (4).

The Leica HER2 FISH System - 30 Test contains the LSI HER2 DNA probe, a 226 Kb SpectrumOrange™ directly labeled fluorescent DNA probe specific for the HER2 gene locus (17q11.2-q12) and the CEP17 DNA probe, a 5.4 Kb SpectrumGreen™ directly labeled fluorescent DNA probe specific for the alpha satellite DNA sequence at the centromeric region of chromosome 17 (17p11.1-q11.1). The probe solution has been specially formulated and validated for use on the BOND-MAX and BOND-III System and should not be modified or used in a manual setting.

Clinical Concordance Summary Leica BOND-MAX System

The Leica HER2 FISH System - 30 Test was developed to provide a fully automated alternative to current methodologies used to determine HER2 gene amplification status. The performance of the Leica HER2 FISH System - 30 Test on the BOND-MAX System was evaluated in an independent study comparing the results of the Leica HER2 FISH System - 30 Test to the Abbott Molecular PathVysion HER-2 DNA Probe Kit Assay on 300 breast tumor specimens and on 109 adenocarcinomas of the stomach (including gastroesophageal junction). None of these tumor specimens were obtained from patients in the Herceptin clinical studies. The results on breast tissue indicated a 99.33% concordance in a 2x2 analysis (95% confidence intervals of 97.61–99.92%). The results on adenocarcinomas of the stomach (including gastroesophageal junction tissue) indicated a 98.17% concordance in a 2x2 analysis (95% confidence intervals of 93.53–99.78%). The concordance data also indicates that a positive result with the Leica HER2 FISH System - 30 Test is highly likely to correspond with a positive result on the Abbott Molecular PathVysion HER-2 DNA Probe Kit assay. The Leica HER2 FISH System - 30 Test is interpreted as negative for HER2 gene amplification when the HER2:CEP17 gene ratio is less than 2.0 and positive when the HER2:CEP17 gene ratio is greater than or equal to 2.0. Equivocal (borderline) results, where the HER2:CEP17 gene ratio is between or equal to 1.8-2.2, should be interpreted with caution. Count an additional 20 nuclei and recalculate the ratio.

Clinical Concordance Summary Leica BOND-III System

The Leica HER2 FISH System - 30 Test was developed to provide a fully automated alternative to current methodologies used to determine HER2 gene amplification status. The performance of the Leica HER2 FISH System - 30 Test on the BOND-III System was evaluated in an independent study comparing the results of the Leica HER2 FISH System - 30 Test to the Abbott Molecular PathVysion HER-2 DNA Probe Kit Assay on 300 breast tumor specimens. None of these tumor specimens were obtained from patients in the Herceptin clinical studies. The results indicated a 99.67% concordance in a 2x2 analysis (95% confidence intervals of 98.16–99.99%). The concordance data also indicates that a positive result with the Leica HER2 FISH System - 30 Test is highly likely to correspond with a positive result on the Abbott Molecular PathVysion HER-2 DNA Probe Kit assay. The Leica HER2 FISH System - 30 Test is interpreted as negative for HER2 gene amplification when the HER2:CEP17 gene ratio is less than 2.0 and positive when the HER2:CEP17 gene ratio is greater than or equal to 2.0. Equivocal (borderline) results, where the HER2:CEP17 gene ratio is between or equal to 1.8-2.2, should be interpreted with caution. Count an additional 20 nuclei and recalculate the ratio.

Principle of Procedure

The Leica HER2 FISH System - 30 Test contains components required to complete a fluorescence *in situ* hybridization based staining procedure for formalin-fixed, paraffin-embedded tissues. Following appropriate pretreatment, incubation with the ready-to-use LSI HER2/CEP17 Dual Probe and appropriate stringency washing, tissue sections are then dehydrated and mounted with DAPI. Results are interpreted by fluorescence microscopy using the recommended filters at the appropriate wavelengths.

The Leica HER2 FISH System - 30 Test is for use only on the BOND-MAX and BOND-III System.

Components Provided

The materials listed below (Table 1) are sufficient to stain 30 tests (30 slides stained with LSI HER2/CEP17 Dual Probe).

LSI HER2/CEP17 Probe 6.6 mL	Contains ready-to-use LSI HER2/CEP17 Dual Probe. Contains <60% (v/v) formamide.
Post Hybridization Wash 2 9 mL	Contains ready-to-use post hybridization wash solution. Contains <50% (v/v) formamide.
BOND Enzyme Concentrate 2 1 mL	Contains Proteinase K solution at 1.7 mg/mL.
BOND Enzyme Diluent 65 mL	Contains Enzyme Diluent.
BOND Open Container 3 x 7 mL	BOND Open Container used for Enzyme 5.

Table 1: Leica HER2 FISH System - 30 Test Components

Refer to individual MSDS for further product safety information, available from www.LeicaBiosystems.com/TA9217-IFU

Directions For Use

All reagents supplied are formulated specifically for use with this assay and lot numbers are specific for each Leica HER2 FISH System - 30 Test. For the assay to be valid, no substitutions should be made.

Storage and Stability

Store at 2–8 °C. Do not freeze. Return to 2–8 °C immediately after use. Any deviation from these conditions will invalidate the assay. Ensure the Leica HER2 FISH System - 30 Test is used within its designated expiry date. The signs indicating contamination and/or instability of the Leica HER2 FISH System - 30 Test are turbidity of the solutions (except for the probe solution) and odor development. The user must verify storage conditions other than those specified above.

Specimen Preparation

Standard methods of tissue processing should be used for all specimens (20). It is recommended that tissues are prepared in formalin-based fixatives and are routinely processed and paraffin-embedded. For example, specimens should be sampled at a thickness of 3–4 mm and fixed for 18–24 hours in 10% neutral-buffered formalin. The tissues should then be dehydrated in a series of alcohols and cleared through xylene, followed by impregnation with molten paraffin wax, held at no more than 60 °C. Tissue specimens should be sectioned between 4–6 µm.

Tissue sections mounted on charged slides (BOND Plus Slides S21.2113) can be held for up to 12 months at 2–8 °C before staining. Following sectioning, it is recommended that slides are incubated at 60 °C for one hour. Stained sections should be stored at -20 °C to preserve fluorescent signal and prevent fading. Allow stored slides to reach room temperature prior to reading.

Warnings and Precautions

For professional users only.

One or more components in the product are hazardous and may cause harm to the unborn child.

As a rule, persons under 18 years of age are not allowed to work with this product. Users must be carefully instructed in the proper work procedure, the hazardous properties of the product and the necessary safety instructions.

Specimens, before and after fixation, and all materials exposed to them, should be handled as if capable of transmitting infection and disposed of with proper precautions.

Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. Seek medical advice. Consult federal, state or local regulations for disposal of any potentially toxic components.

Minimize microbial contamination of reagents or an increase in nonspecific staining may occur.

Procedure

A. Reagents required but not supplied

- BOND Dewax Solution (AR9222)
- BOND Epitope Retrieval Solution 1 (AR9961)
- BOND Wash Solution x10 Concentrate (AR9590)
- Standard solvents used in fluorescence *in situ* hybridization based assays (eg ethanol, absolute and graded)
- Distilled or de-ionized water
- DAPI Counterstain
- Leica HER2 FISH Control Slides (TA9123)
- BOND Aspirating Probe Cleaning System (CS9100)

B. Equipment required but not supplied

- Pipettes (capable of measuring 1-20 µL and 100 – 1000 µL volumes)
- Charged slides (BOND Plus Slides – S21.2113)
- BOND-MAX (21.0051) or BOND-III (21.2201)
- BOND Universal Coverslips™ (S21.2001, S21.4583 or S21.4611)
- BOND Mixing Stations (S21.1971)
- BOND Slide Label & Print Ribbon (S21.4564)
- Coverslips
- Drying oven (capable of maintaining 60 °C)
- Fluorescence Microscope (60–100x objective) with appropriate light source. Record the number of hours that the bulb has been used and replace the bulb before it exceeds the rated time. Ensure that the lamp is properly aligned.
- Appropriate Fluorescence Filter Set (SpectrumOrange™ – Excitation Peak at 559nm, Emission Peak at 588nm, SpectrumGreen™ – Excitation Peak at 497nm, Emission Peak at 524nm and DAPI – Excitation Peak at 367nm, Emission Peak at 452nm). Multi-bandpass fluorescence microscope filter sets optimized for use with the Leica HER2 FISH System - 30 Test are available for most microscope models. The recommended filter sets for the Leica HER2 FISH System - 30 Test are the DAPI/9-Orange dual bandpass, DAPI/Green dual bandpass, Green/Orange(V.2) dual bandpass and the DAPI/Green/Orange (V.2) triple bandpass.

C. Methodology

- Prior to undertaking this methodology, users are required to be suitably trained in the automated *in situ* fluorescence technique.
- Each test section stained with the LSI HER2/CEP17 Dual Probe enables same cell analysis of both HER2 and centromeric chromosome 17 signals. A subsequent ratio of HER2 to chromosome 17 signals will enable a quantitative value to be assigned to the sample, indicating a negative (non-amplified) or positive (amplified) result. Equivocal (borderline) results (1.8-2.2) should be interpreted with caution. Count an additional 20 nuclei and recalculate the ratio.

D. BOND Enzyme Pretreatment

Prior to staining dilute supplied BOND Enzyme Concentrate 2 at a 1:300 dilution using supplied BOND Enzyme Diluent in one of the BOND Open Containers provided. For example, to stain 10 slides prepare 3 mL of working enzyme solution by diluting 10 µL of BOND Enzyme Concentrate 2 in 2990 µL of BOND Enzyme Diluent. It is recommended that the enzyme is freshly prepared before each staining run and that a minimum volume of 900 µL be used per run.

E. Default Staining Protocol

It is recommended that the Leica HER2 FISH System - 30 Test is used with the recommended default staining protocol shown in Table 2 below.

Protocol Type	Protocol Name
Staining	*FISH Protocol A
Preparation	*Dewax
HIER	*HIER 25 min with ER1 (97)
Enzyme	*Enzyme 5 for 25 min
Denaturation	*D10
Hybridization	*ISH Hybridization (12Hr)

Table 2: Default Leica HER2 FISH System - 30 Test Staining Protocol

F. Procedure Steps

These instructions should be read in conjunction with the BOND-MAX and BOND-III System user manual. A new BOND Universal Covertile should be used with each slide. The use of BOND Universal Covertiles, which have previously been utilized for either immunohistochemical or *in situ* hybridization staining have not been validated with this test.

1. On the BOND-MAX and BOND-III System, ensure the bulk and hazardous waste containers have enough capacity to perform the required staining runs.
2. Ensure there is adequate alcohol, distilled or de-ionized water, BOND Dewax Solution, BOND Epitope Retrieval Solution 1 and BOND Wash Solution in the bulk reagent containers to perform the required staining runs.
3. Ensure that a clean BOND Mixing Station is installed.
4. Turn on the BOND-MAX and BOND-III System.
5. Turn on the PC attached to the BOND-MAX and BOND-III System.
6. Open the BOND software.
7. For a new Leica HER2 FISH System - 30 Test kit, scan the reagent tray barcode with the handheld scanner to enter the system into the BOND reagent inventory (Single barcode only).


8. Prepare BOND Enzyme 5 in the supplied BOND Open Container at a dilution of 1:300. For example, for 10 slides add 10µL of BOND Enzyme Concentrate 2 to 2990 µL of BOND Enzyme Diluent.
9. Scan in supplied BOND Open Container and register as **Bond Enzyme 5**.
10. Go to the Slide setup screen and click **Add case**.
11. Enter details for the first case. Ensure the dispense volume is set to **150 µL** and the preparation protocol is ***Dewax**. Click **OK**.
12. With the case highlighted in the Slide setup screen click **Add slide**.
13. First, add patient test slides. Ensure tissue type is set to **Test tissue**.
14. Select staining mode **Single**.
15. Select process **ISH**.
16. Select ***LSI HER2/CEP17 Dual Probe – 30 Test** from the probe list. The Protocols tab defaults to the correct staining protocol (***FISH Protocol A**), HIER protocol (***HIER 25 min with ER1 (97)**), EIER protocol (***Enzyme 5 for 25 min**), denaturation (***D10**) and hybridization (***ISH Hybridization (12Hr)**).
17. Repeat steps 10 to 16 until patient test slides and controls (Leica HER2 FISH Control slides and/or in-house controls) have been created. Print slide labels.
18. Label slides appropriately.
19. Open the lids of all Leica HER2 FISH System - 30 Test containers and load the reagent tray onto the Leica BOND-MAX and BOND-III System.
20. Apply new Covertiles to each slide.
21. Load the slide tray onto the BOND-MAX and BOND-III System and press the **Load/Unload** button.
22. Confirm that the slides have been scanned and click the **Run (Play)** button on the System status screen to commence the run immediately (for the Leica HER2 FISH System - 30 Test it is recommended that this assay is run overnight utilizing the delayed start functionality).
23. Ensure that the tray indicator field displays **Proc (OK)** and batch number and finish time are displayed.
24. When the run is completed press the **Load/Unload** button and remove the slide tray from the BOND-MAX and BOND-III System.
25. Remove Covertiles and rinse the slides in de-ionized water.
26. Dehydrate rapidly in two changes of alcohol, air dry.
27. Dispense 20µL of DAPI directly onto the sample.
28. Apply coverslip and allow the solution to spread to its full extent, taking care to remove any air bubbles.
29. Seal edge of coverslip with nail varnish, or similar sealant.
30. Place slides in dark to facilitate signal development before viewing under fluorescence microscope.
31. To preserve signal intensity store stained slides at -20 °C.

G. Slide Storage

Store stained slides at -20 °C in the dark. Allow slides to reach room temperature prior to viewing following removal from -20 °C.

Signal Assessment and Enumeration

To assess the signal quality and enumerate the HER2 and CEP17 signals follow the process below:



Recommended Method for LSI HER2 to CEP17 Ratio Determination

To determine the LSI HER2 to CEP17 ratio, use the following method:

1. Record and determine the number of LSI HER2 and CEP17 signals in 20 nuclei (see Figure 2 Leica HER2 FISH System - 30 Test score sheet below).
2. Total all of the LSI HER2 signals. This represents the total LSI HER2 signals for the count, e.g. 143.
3. Total all of the CEP17 signals. This represents the total CEP17 signals for the count, e.g. 48.
4. To calculate the final result, use the following calculation:
Total LSI HER2 signals divided by Total CEP17 signals,
e.g. 143/48 equals a ratio of 2.98, which is positive for HER2 amplification.

Important Note: If the LSI HER2 to CEP17 ratio is equivocal (1.80 - 2.20), count an additional 20 nuclei and recalculate the ratio.

Results should be reported as follows:

1. If the ratio is <2 , HER2 gene amplification was not observed
2. If the ratio is ≥ 2 , HER2 gene amplification was observed

Important Note: A ratio at or near the cut-off (1.80 - 2.20) should be interpreted with caution, as described above.

Leica HER2 FISH System - 30 Test Interpretation Guide




Figure 1: Interpretation Guide

Leica HER2 FISH System - 30 Test Score Sheet

20 Nuclei Signal Count					
Nucleus #	HER2 Copy Number	CEP17 Copy Number	Nucleus #	HER2 Copy Number	CEP17 Copy Number
1			11		
2			12		
3			13		
4			14		
5			15		
6			16		
7			17		
8			18		
9			19		
10			20		
Total 1-10			Total 11-20		
		HER2	CEP17	HER2:CEP17 Amplification ratio	
Total Score 1-20					
Average Per Cell					

Figure 2: Sample Score Sheet

Automated Ariol Method for HER2 FISH Determination

The use of the Ariol PathVysion® digital scoring application as an aid in interpretation was independently validated on a different cohort of samples for use with the Leica HER2 FISH System. The Ariol PathVysion digital scoring application, when used in conjunction with the Leica HER2 FISH System is for In Vitro Diagnostic Use. When used with the Leica HER2 FISH System the Ariol PathVysion application should be calibrated for use with tissue control slides, **not** the Leica HER2 FISH Control Slides (TA9123).

All diagnostic decisions are made by the qualified clinician.

For further information please refer to the Ariol Operator's manual.

Quality Control

Use of Control Slides

It is recommended that a Leica HER2 FISH Control Slide is included in each test run to monitor assay performance and to assess the accuracy of signal enumeration. Control slides should be run for each staining batch on the BOND-MAX and BOND-III System and with each new reagent lot. In addition, individual users may choose to use their own control material.

Assess control slide quality and perform signal enumeration according to the instructions in the **Signal Assessment and Enumeration** section. The criteria for slide quality must be satisfied and the HER2:CEP17 ratio results should be within the established ranges for acceptable test performance. See Table 3 for acceptance criteria of the Leica HER2 FISH Control Slides.

Cell Line	Bond Oracle HER2 IHC System Profile	HER2 ReceptorLoad per cell*	Leica HER2 FISH System - 30 Test HER2:CEP17 Acceptance Criteria
SKBr-3	3+	4.3 x 10 ⁵	HER2 amplification is observed
MDA-MB-453	2+	1.4 x 10 ⁵	HER2/CEP17 gene ratio should be between 1.5 – 2.5
MDA-MB-175	1+	6.3 x 10 ⁴	HER2 amplification is not observed
MDA-MB-231	0	9.3 x 10 ³	HER2 amplification is not observed

*HER2 receptor load analysis as assessed by flow cytometry

Table 3: Leica HER2 FISH Control Slide Interpretation.

If assay controls fail, FISH results for that case should not be reported. If control slides fail to meet the slide acceptance criteria, the Leica HER2 FISH System - 30 Test may have performed inadequately. In this instance, a repeat test with fresh control slides and patient specimen slide(s) will be required. If the results are outside of the specified range, but the control slides meet the acceptance criteria for quality, repeat screening of the same slide may be appropriate since the enumeration may not have been performed correctly. Consult the troubleshooting guide (Table 6) in the event of hybridization failure, with either the specimen or control slide(s).

For clinical specimens, when interpretation of the hybridization signal is difficult and there is insufficient specimen sample for re-assay, the test is uninformative. If there are insufficient cells for analysis, the test is uninformative.

Patient specimens should be controlled according to standard laboratory operating procedures. Signal quality and enumeration results should be documented on an appropriate report form.

Limitations

A. General Limitations

FISH is a technique that requires specialized training in all aspects of the procedure (including the selection of appropriate reagents, tissue, fixation, processing and slide preparation) and interpretation. Tissue staining is dependent on the handling, fixation and processing of the

tissue prior to staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce morphological artifacts, nucleic acid degradation, background fluorescence or false negative results. Inconsistent results may be due to variations in fixation, embedding methods, or inherent irregularities within the tissue (21). Excessive or incomplete counterstaining may also compromise correct interpretation of the results.

Non-specific staining as a result of unbound probe has a scattered, granular appearance and may be visualized at or distant from the expected hybridization site. Use intact cells for interpretation of staining results. Necrotic or degenerated cells may stain non-specifically (22). Unexpected FISH staining, or variations in the staining, may be a result of alterations in the expression levels of the encoding genes. Any change in expected staining patterns should be interpreted in association with all other diagnostic investigations. Staining interpretation should be complemented by morphological studies and the use of suitable control material, and should be evaluated within the context of the patient's clinical history and any other diagnostic tests, by a qualified pathologist.

The performance of the assay (i.e. assessment of adequacy of control materials) and the interpretation of any staining or its absence must be carried out in an appropriately accredited/licensed laboratory under the supervision of a suitably qualified and experienced pathologist, who is responsible for the overall assessment of the *in situ* hybridization assay and its interpretation. False positive results in FISH may be due to cross-reactivity of the probe to other nucleic acid sequences and/or nonspecific binding. Appropriate controls must be employed and documented, and tests should take into account all relevant expiration dates.

Technical and interpretational variation may also be seen when FISH is utilized on cell line derived materials (23).

B. Product Specific Limitations

This product is not designed for use in any other DNA-based diagnostic assay.

Do not replace Leica HER2 FISH System - 30 Test reagents with any other components either supplied by Leica Biosystems or by other manufacturers. To do so will invalidate the assay. The user must validate any deviation from the recommended procedures.

It is recommended that tissues fixed only in formalin-based fixatives be used in the assay. The use of any other type of fixative may invalidate the assay.

Tissue sections cut outside of the recommended thickness range have not been validated. The use of any other section thickness may invalidate the assay.

Clinical Concordance of HER2 FISH System - 30 Test to Abbott Molecular PathVysion HER-2 DNA Probe Kit - Breast

This study examined the suitability of the Leica HER2 FISH System - 30 Test for use as an aid in determination of treatment for Herceptin (trastuzumab) therapy. The study was designed to examine the concordance between the Leica HER2 FISH System - 30 Test and a previously approved diagnostic device, the Abbott Molecular PathVysion HER-2 DNA Probe Kit, considered as the 'gold standard' for this assay on breast tissue. The acceptance criterion for testing was that the lower limit of the 95% one-sided confidence interval is above 90% between the Leica HER2 FISH System - 30 Test and the manual Abbott Molecular PathVysion HER-2 DNA Probe Kit, between positive (amplified) and negative (non-amplified) formalin-fixed, paraffin-embedded (FFPE) invasive breast cancer cases.

The study was conducted as a three-site, masked evaluation of clinical invasive breast carcinoma samples. Each of the investigational sites were supplied with archived formalin-fixed, paraffin-embedded invasive breast carcinoma tissue blocks with known HER2 oncoprotein expression levels. A cohort of 300 specimens consisting of 75, 0/1+ previously characterized IHC cases; 150, 2+ previously characterised IHC cases; and 75, 3+ previously characterized IHC cases were selected, and split equally across each of the three investigational trial sites.

All cases were stained with the manual Abbott Molecular PathVysion HER-2 DNA Probe Kit Assay according to the manufacturer's instructions for use, as specified in the package insert. Sequential sections from each case were then stained with the Leica HER2 FISH System - 30 Test on the BOND-MAX and BOND-III System.

All stained slides were masked and scored in a randomized fashion by a single trained observer at each of the three investigational trial sites. Scores were interpreted as negative with a calculated HER2/CEP17 gene ratio of <2.0 and positive with a calculated HER2/CEP17 gene ratio of ≥ 2.0 . Data was then analyzed for concordance, positive staining agreement and negative staining agreement.

2x2 Concordance Results BOND-MAX System - Breast

Data was grouped as negative (<2.00) or positive (≥ 2.00) for a 2x2 analysis. The observed agreement for 300 samples between the two tests in a 2x2 analysis show a concordance of 99.33% (298/300) with a 95% CI of 97.61–99.92% for the BOND-MAX System.

The percentage Positive Agreement (sensitivity) or the ability of the Leica HER2 FISH System - 30 Test to correctly identify Abbott Molecular PathVysion HER-2 DNA Probe assay positive cases (the percentage of specimens scored positive by both the Leica HER2 FISH System - 30 Test and manual Abbott Molecular PathVysion HER-2 DNA Probe Kit out of all the Abbott Molecular PathVysion HER-2 DNA Probe Kit positive cases) was 99.03% (102/103).

The percentage Negative Agreement (specificity) or the ability of the test to correctly identify Abbott Molecular PathVysion HER-2 DNA Probe Kit negative cases (the percentage of specimens scored negative by the Leica HER2 FISH System - 30 Test and Abbott Molecular PathVysion HER-2 DNA Probe Kit out of all the Abbott Molecular PathVysion HER-2 DNA Probe Kit negative cases) was 99.49% (196/197). See Table 4.

		Abbott Molecular PathVysion HER-2 DNA Probe Kit		
		Negative (<2.0)	Positive (≥ 2.0)	Totals
Leica HER2 FISH System - 30 Test BOND-MAX	Negative (<2.0)	196	1	197
	Positive (≥ 2.0)	1	102	103
	Totals	197	103	300

Overall Concordance (95% CI) = 99.33% (97.61 – 99.92%)

Table 4. 2x2 concordance of Leica HER2 FISH System - 30 Test on the BOND-MAX System with Abbott Molecular PathVysion HER-2 DNA Probe Kit on breast tissue.

2x2 Concordance Results BOND-III System - Breast

Data was grouped as negative (<2.00) or positive (≥2.00) for a 2x2 analysis. The observed agreement for 300 samples between the two tests in a 2x2 analysis show a concordance of 99.67% (299/300) with a 95% CI of 98.16–99.99% for the BOND-III System.

The percentage Positive Agreement (sensitivity) or the ability of the Leica HER2 FISH System - 30 Test to correctly identify Abbott Molecular PathVysion HER-2 DNA Probe Kit assay positive cases (the percentage of specimens scored positive by both the Leica HER2 FISH System - 30 Test and manual Abbott Molecular PathVysion HER-2 DNA Probe Kit out of all the Abbott Molecular PathVysion HER-2 DNA Probe Kit positive cases) was 99.03% (102/103).

The percentage Negative Agreement (specificity) or the ability of the test to correctly identify Abbott Molecular PathVysion HER-2 DNA Probe Kit negative cases (the percentage of specimens scored negative by the Leica HER2 FISH System - 30 Test and Abbott Molecular PathVysion HER-2 DNA Probe Kit out of all the Abbott Molecular PathVysion HER-2 DNA Probe Kit negative cases) was 100% (197/197). See Table 5.

		Abbott Molecular PathVysion HER-2 DNA Probe Kit		
		Negative (<2.0)	Positive (≥2.0)	Totals
Leica HER2 FISH System - 30 Test BOND-III	Negative (<2.0)	197	1	198
	Positive (≥2.0)	0	102	102
	Totals	197	103	300

Overall Concordance (95% CI) = 99.67% (98.16 – 99.99%).

Table 5. 2x2 concordance of Leica HER2 FISH System - 30 Test on the BOND-III System with Abbott Molecular PathVysion HER-2 DNA Probe Kit on breast tissue.

In conclusion, the data generated in this study demonstrates that the Leica HER2 FISH System - 30 Test can be used as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered, based upon its high concordance with Abbott Molecular PathVysion HER-2 DNA Probe Kit, a previously approved diagnostic test for this indication.

Clinical Concordance of HER2 FISH System - 30 Test to Abbott Molecular PathVysion HER-2 DNA Probe Kit - Gastric

This study examined the suitability of the Leica HER2 FISH System - 30 Test for use as an aid in determination of treatment for Herceptin (trastuzumab) therapy. The study was designed to examine the concordance between the Leica HER2 FISH System - 30 Test and a previously approved diagnostic device, the Abbott Molecular PathVysion HER-2 DNA Probe Kit, considered as the 'gold standard' for this assay on gastric tissue. The acceptance criterion for testing was that the lower limit of the 95% one-sided confidence interval is above 90% between the Leica HER2 FISH System - 30 Test and the manual Abbott Molecular PathVysion HER-2 DNA Probe Kit, between positive (amplified) and negative (non-amplified) formalin-fixed, paraffin-embedded (FFPE) adenocarcinomas of the stomach (including gastroesophageal junction).

The study was conducted as an evaluation of clinical invasive gastric adenocarcinoma samples. Testing was performed on archived formalin-fixed, paraffin-embedded gastric adenocarcinoma tissue blocks with known HER2 gene expression levels. A cohort of 109 specimens consisting of 50 amplified cases and 59 non-amplified cases were selected.

All cases were stained with the manual Abbott Molecular PathVysion HER-2 DNA Probe Kit Assay according to the manufacturer's instructions for use, as specified in the package insert. Sequential sections from each case were then stained with the Leica HER2 FISH System - 30 Test on the BOND-MAX System.

All stained slides were scored in a randomized fashion by a single trained observer. Scores were interpreted as negative with a calculated HER2/CEP17 gene ratio of <2.0 and positive with a calculated HER2/CEP17 gene ratio of ≥ 2.0 . Data was then analyzed for concordance, positive staining agreement and negative staining agreement.

2x2 Concordance Results BOND-MAX System - Gastric

Data was grouped as negative (<2.00) or positive (≥ 2.00) for a 2x2 analysis. The observed agreement for 109 samples between the two tests in a 2x2 analysis show a concordance of 98.17% (107/109) with a 95% CI of 93.53–99.78% for the BOND-MAX System.

The percentage Positive Agreement (sensitivity) or the ability of the Leica HER2 FISH System - 30 Test to correctly identify Abbott Molecular PathVysion HER-2 DNA Probe assay positive cases (the percentage of specimens scored positive by both the Leica HER2 FISH System - 30 Test and manual Abbott Molecular PathVysion HER-2 DNA Probe Kit out of all the Abbott Molecular PathVysion HER-2 DNA Probe Kit positive cases) was 96.00% (48/50).

The percentage Negative Agreement (specificity) or the ability of the test to correctly identify Abbott Molecular PathVysion HER-2 DNA Probe Kit negative cases (the percentage of specimens scored negative by the Leica HER2 FISH System - 30 Test and Abbott Molecular PathVysion HER-2 DNA Probe Kit out of all the Abbott Molecular PathVysion HER-2 DNA Probe Kit negative cases) was 100% (59/59). See Table 6.

		Abbott Molecular PathVysion HER-2 DNA Probe Kit		
		Negative (<2.0)	Positive (≥ 2.0)	Totals
Leica HER2 FISH System - 30 Test BOND-MAX	Negative (<2.0)	59	2	61
	Positive (≥ 2.0)	0	48	48
	Totals	59	50	109

Overall Concordance (95% CI) = 98.17% (93.53–99.78%)

Table 6. 2x2 concordance of Leica HER2 FISH System - 30 Test on the BOND-MAX System with Abbott Molecular PathVysion HER-2 DNA Probe Kit on gastric tissue.

Precision Testing – BOND-MAX System

A. Within Run Precision Study

The within run precision study was performed in a randomized and blinded fashion. Within run precision testing of the Leica HER2 FISH System - 30 Test was evaluated at a single investigational site on 540 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of within run precision enabled a larger volume of cases covering a wider range of HER2 expression within a single run on a single instrument.

On enumeration of the slides stained in the Within Run Precision Study, 532/540 cases evaluated demonstrated a concordant result giving an overall concordance of 98.52% with a lower 95% CI of 97.10%.

B. Within Instrument Precision Study

The within instrument precision study was performed in a randomized and blinded fashion. Within instrument precision testing of the Leica HER2 FISH System - 30 Test was evaluated at a single investigational site on 1620 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of within instrument precision enabled a larger volume of cases covering a wider range of HER2 expression within multiple runs on a single instrument.

On enumeration of the slides stained in the Within Instrument Precision Study, 1620/1620 cases evaluated demonstrated a concordant result giving an overall concordance of 100% with a lower 95% CI of 99.82%.

C. Between Run Precision Study

The between run precision study was performed in a randomized and blinded fashion. Between run precision testing of the Leica HER2 FISH System - 30 Test was evaluated at a single investigational site on 900 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of between run, day-to-day precision testing enabled a larger volume of cases covering a wider range of HER2 expression to be tested between runs on different days.

On enumeration of the slides stained in the Between Run Precision Study, 894/900 cases evaluated demonstrated a concordant result giving an overall concordance of 99.33% with a lower 95% CI of 98.55%.

D. Between Laboratory Precision Study

The between laboratory precision study was performed in a randomized and blinded fashion. Between laboratory precision testing of the Leica HER2 FISH System - 30 Test was evaluated between three investigational sites on 513 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of between laboratory precision testing enabled a larger volume of cases covering a wider range of HER2 expression to be tested between runs on multiple instruments.

On enumeration of the slides stained in the Between Laboratory Precision Study, 510/513 cases evaluated demonstrated a concordant result giving an overall concordance of 99.42% with a lower 95% CI of 98.30%.

E. Between Observer Precision Study

The between observer precision study was performed in a randomized and blinded fashion. Between observer reproducibility testing of the Leica HER2 FISH System - 30 Test was evaluated between three investigational sites. A single experienced observer at each investigational site was used. Eighteen whole section breast cancer cases were used for between observer precision, reflecting samples types used in the clinical setting.

On enumeration of the slides stained in the Between Observer Precision Study, 53/54 cases evaluated demonstrated a concordant result giving an overall concordance of 98.15% with a lower 95% CI of 90.11%

F. Lot-to-Lot Precision Study

The lot-to-lot precision study was performed in a randomized and blinded fashion. Lot-to-Lot precision was determined on three independently manufactured lots of the Leica HER2 FISH System - 30 Test, manufactured under Good Manufacturing Practice (GMP). Each lot was tested at a single investigational site on 540 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of lot-to-lot reproducibility enables a larger volume of cases covering a wider range of HER2 expression to be tested between lots.

On enumeration of the slides stained in the Lot-to-Lot Precision Study, 534/540 cases evaluated demonstrated a concordant result giving an overall concordance of 98.89% with a lower 95% CI of 97.60%.

Precision Testing – BOND-III System

G. Within Run Precision Study

The within run precision study was performed in a randomized and blinded fashion. Within run precision testing of the Leica HER2 FISH System - 30 Test was evaluated at a single investigational site on 540 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of within run precision enabled a larger volume of cases covering a wider range of HER2 expression within a single run on a single instrument.

On enumeration of the slides stained in the Within Run Precision Study, 540/540 cases evaluated demonstrated a concordant result giving an overall concordance of 100% with a lower 95% CI of 99.45%.

H. Within Instrument Precision Study

The within instrument precision study was performed in a randomized and blinded fashion. Within instrument precision testing of the Leica HER2 FISH System - 30 Test was evaluated at a single investigational site on 1620 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of within instrument precision enabled a larger volume of cases covering a wider range of HER2 expression within multiple runs on a single instrument.

On enumeration of the slides stained in the Within Run Precision Study, 1620/1620 cases evaluated demonstrated a concordant result giving an overall concordance of 100% with a lower 95% CI of 99.82%.

I. Between Run Precision Study

The between run precision study was performed in a randomized and blinded fashion. Between run precision testing of the Leica HER2 FISH System - 30 Test was evaluated at a single investigational site on 900 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of between run, day-to day precision testing enabled a larger volume of cases covering a wider range of HER2 expression to be tested between runs on different days.

On enumeration of the slides stained in the Between Run Precision Study, 891/900 cases evaluated demonstrated a concordant result giving an overall concordance of 99.00% with a lower 95% CI of 98.11%.

J. Between Laboratory Precision Study

The between laboratory precision study was performed in a randomized and blinded fashion. Between laboratory precision testing of the Leica HER2 FISH System - 30 Test was evaluated between three investigational sites on 513 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of between laboratory precision testing enabled a larger volume of cases covering a wider range of HER2 expression to be tested between runs on multiple instruments.

On enumeration of the slides stained in the Between Laboratory Precision Study, 511/513 cases evaluated demonstrated a concordant result giving an overall concordance of 99.61% with a lower 95% CI of 98.60%.

K. Between Observer Precision Study

The between observer precision study was performed in a randomized and blinded fashion. Between observer reproducibility testing of the Leica HER2 FISH System - 30 Test was evaluated between three investigational sites. A single experienced observer at each investigational site was used. Eighteen whole section breast cancer cases were used for between observer precision, reflecting samples types used in the clinical setting.

On enumeration of the slides stained in the Between Observer Precision Study, 53/54 cases evaluated demonstrated a concordant result giving an overall concordance of 98.15% with a lower 95% CI of 90.11%.

L. Lot-to-Lot Precision Study

The lot-to-lot precision study was performed in a randomized and blinded fashion. Lot-to-Lot precision was determined on three independently manufactured lots of Leica HER2 FISH System - 30 Test, manufactured under Good Manufacturing Practice (GMP). Each lot was tested at a single investigational site on 540 previously HER2 characterized TMA samples containing formalin-fixed paraffin-embedded breast cancer cases. The use of TMAs for the determination of lot-to-lot reproducibility enables a larger volume of cases covering a wider range of HER2 expression to be tested between lots.

On enumeration of the slides stained in the Lot-to-Lot Precision Study, 540/540 cases evaluated demonstrated a concordant result giving an overall concordance of 100% with a lower 95% CI of 99.45%.

Assay Robustness

Robustness studies were performed on the BOND-MAX and BOND-III System to determine the assay tolerance range for heat retrieval time and temperature; enzyme retrieval time, temperature and concentration; denaturation time and temperature; hybridization time and temperature; and stringency wash time and temperature. Robustness studies using the default BOND-MAX and BOND-III System protocol were also performed outside the recommended limits as defined in the FDA/ORA guidance document ORA LAB5.3 Rev1.7 for temperature and humidity.

- No difference in amplification status was observed when the default temperature for each heat dependent step was raised by 4 °C or decreased by 4 °C, when compared to the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default temperatures and these temperatures are recommended.
- No difference in amplification status was observed when the heat induced epitope retrieval (HIER) time was performed for 20 minutes and 30 minutes at 97 °C with BOND ER1 solution, when compared to the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default time of 25 minutes and this incubation time is recommended.
- No difference in amplification status was observed when the enzyme induced epitope retrieval (EIER) time was performed for 15 minutes and 35 minutes at 37 °C, when compared to the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default time of 25 minutes and this incubation time is recommended.
- No difference in amplification status was observed when the enzyme induced epitope retrieval (EIER) enzyme concentration was performed with enzyme concentrate/enzyme diluent ratios of 1:200 and 1:500 using the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default concentration of 1:300 and this dilution is recommended.
- No difference in amplification status was observed when the denaturation time was performed for 5 minutes and 15 minutes, when compared to the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default time of 10 minutes and this denaturation time is recommended.

- No difference in amplification status was observed when the hybridization time was performed for 9 hours and 15 hours when compared to the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default time of 12 hours and this hybridization time is recommended.
- No difference in amplification status was observed when the post hybridization wash time was performed for 2 minutes, 5 minutes, and 7 minutes, when compared to the default Leica HER2 FISH System - 30 Test protocol. Highest quality ratings were observed at the default time of 4 minutes and this post hybridization wash time is recommended.
- No difference in amplification status was observed when the Leica HER2 FISH System - 30 Test was performed at 28 °C and 30% relative humidity and 16 °C and 80% relative humidity, when compared to the default Leica HER2 FISH System - 30 Test protocol performed at ambient conditions.

Operations performed outside of the tested assay robustness recommended parameters have not been validated. The use of any other testing parameter may invalidate the assay.

The above text describes the conditions tested and the results from the study. Note that Leica did not test all possible combinations of conditions and does not recommend using non-default ranges for all conditions. The default Leica HER2 FISH Staining Protocol is outlined in Table 2.

Troubleshooting

Problem	Probable Cause	Remedial Action
No or weak fluorescent signal/staining	Inappropriate fixation or processing of test specimen	Ensure a formalin-based fixative is used and that processing schedules are suitable for the specimen undergoing testing.
	Leica HER2 FISH System - 30 Test is being used outside its expiry date	Ensure the Leica HER2 FISH System - 30 Test used is within its specified expiry date.
	Incorrect protocol selection	Ensure appropriate default to *FISH Protocol A in the staining protocol field of the Add slide dialog.
	Inappropriate bulk reagents dispensed	Ensure all BOND reagents have been allocated to appropriate bulk containers and placed into appropriate positions on the instrument.
	Inadequate deparaffinization of slides	Ensure *Dewax mode is selected in the Preparation field of the Add slide dialog.
	Inappropriate pretreatment	Ensure default pretreatment (HIER and Enzymatic Digestion) protocols are selected. Adjust pretreatment protocol (HIER or Enzymatic Digestion) if required.
	Inadequate denaturation	Ensure appropriate default denaturation *D10 is selected.
	Inadequate hybridization	Ensure appropriate default hybridization *H12 is selected. Extend hybridization time if required.
	Excess post hybridization washing	Decrease post hybridization wash incubation time.
	Run aborted prior to completion	Using BOND software, confirm the presence of any reportable errors during the staining run and address as instructed by the BOND software.
	Inappropriate fluorescence microscopy equipment <ul style="list-style-type: none"> • Inappropriate filter set • Incorrect lamp • Expired lamp • Incorrect oil type 	<p>Ensure that all fluorescence microscopy equipment used is appropriate for the assay being performed, confirm:</p> <ul style="list-style-type: none"> • Appropriate filter set • Appropriate lamp • Good lamp strength • Appropriate oil for use in oil immersion microscopy
	Over exposure to UV light (photobleaching)	Store slides before and after assessment in the dark to preserve fluorescent signals. To maintain signal for long term storage store slides at -20 °C.

Problem	Probable Cause	Remedial Action
Nonspecific background fluorescent signal/staining	Inadequate post hybridization washing	Increase post hybridization wash incubation time.
	Inappropriate bulk reagents dispensed	Ensure all BOND reagents have been allocated into appropriate bulk containers and placed into appropriate positions on the instrument.
	Inadequate deparaffinization of slides	Ensure Dewax is selected in the Preparation field of the Add slide dialog.
	Nonspecific cross-reaction with areas of tissue necrosis	Ensure a formalin-based fixative is used and that processing schedules are suitable for the specimen undergoing testing. If possible, retest case using another block. If this is not possible, assess in conjunction with a corresponding H&E stained section, and select areas which show best fixation patterns.
	Sections adhered to slides using alternative adhesives	Use BOND Plus Slides (S21.2113).
Poor preservation of tissue morphology	Inadequate tissue fixation and processing	Ensure a formalin-based fixative is used and that processing schedules are suitable for the specimen undergoing testing. If possible, retest case using another block. If this is not possible, assess in conjunction with a corresponding H&E stained section, and select areas which show best fixation patterns.
	Inappropriate pretreatment	Adjust pretreatment protocol (HIER or Enzymatic Digestion).
Tissue detached from patient/control slide(s)	Use of incorrect type of slides or inadequate draining of section	Ensure appropriate slides are used for patient/control sections (e.g. BOND Plus Slides S21.2113). Ensure slides receive adequate draining and are incubated for 1 hour at 60 °C.

Table 7. Leica HER2 FISH System - 30 Test Troubleshooting Guide.

If any problems associated with the Leica HER2 FISH System - 30 Test fall outside the scope of the troubleshooting guide please contact your local Leica Biosystems Technical Services Department or Distributor for assistance.

References

1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor related protein. *Nature* 1986;319:226–30.
2. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. *New Biologist* 1990; 2: 992–1003.
3. Wolff A.C., Hammond E.H., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Journal of Clinical Oncology* 25, 1-28, 2007.
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177-182.
5. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. *Journal of Clinical Oncology* 1992;10:7:1049-1056.
6. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. *British Journal of Cancer* 1991;63:434-438.
7. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. *Cancer Research* 1990;50:4332-4337.
8. Tandon AK, Clark GM, Chamness AU, et al. HER-2/neu oncogene protein and prognosis in breast cancer. *Journal of Clinical Oncology* 1989; 7:1120-1128.
9. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F et. al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). *Journal of Clinical Oncology* 2009; 27: LBA4509.
10. Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proceedings of the National Academy of Science USA* 1992; 89: 4285–9.
11. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. *Molecular & Cell Biology* 1989; 9: 1165–72.
12. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. *Cancer Immunology and Immunotherapy* 1993; 37: 255–63.
13. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. *Cancer Research* 1998; 58: 2825–31.
14. Ellis I.O., Bartlett J., Dowsett M., Humphreys S., Jasani B., Miller K., Pinder S.E., Rhodes A. and Walker R. Best practise No. 176: Updated recommendations for Her-2 testing in the UK. *Journal of Clinical Pathology* 57; 233-237, 2004.
15. Walker R.A, Bartlett, J., Dowsett, M., Ellis, I., Hanby, A., Jasani, Miller, K., Pinder, S. HER2 Testing in the UK – further update to recommendations. *Journal of Clinical Pathology* 2007.054866
16. Press MF, Zhou JY, Ma Y, et al. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization in invasive breast carcinoma. In: *FISH: Clinical Applications in Cancer and Genetics* February 8-11, 1994; Lake Tahoe, CA.
17. Pauletti G, Singh R, Press MF, et al. HER-2/neu gene amplification detected by fluorescence in situ hybridization: A comparative study with other techniques. Abstract 3247, *Proceedings of the American Association for Cancer Research* 1994 35:545.
18. Szöllösi J, Balázs M, Feuerstein BG, et al. Phenotype genotype relationship in erbB-2 amplification. *International Society for Analytical Cytology* 1994 Abstracts. 92. Abstract 536D.
19. Kallioniemi O, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. *Proceedings of the National Academy of Sciences* 1992;89:5321-5325.
20. The National Committee for Clinical Laboratory Standards (NCCLS). Quality assurance for immunocytochemistry; Approved guideline. NCCLS document MM4-A (1-56238-396-5) NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 1999; 19087–1898: USA
21. Nadji, M. and Morales, A. R. Immunoperoxidase, part I: the techniques and its pitfalls. *Laboratory Medicine* 1983; 14: 767.

22. Jackson P. 2007. Quality Assurance in Immunohistochemistry. In: Immunohistochemistry, 2007 (ed. Renshaw S), PP 205–237. Scion Publishing Ltd.
23. Bartlet JMS, Ibrahim M, et al External Quality Assurance of HER2 FISH Testing: Results of a UK NEQAS Pilot Scheme. Journal of Clinical Pathology. 2006.

License Agreement

This product contains PathVysion FISH probes supplied by Abbott Molecular Inc.

PathVysion, LSI and CEP are a trademark of Abbott Molecular Inc. All Rights Reserved. Used under License.









Amendments to Previous Issue

Gastric data added.

Date of Issue

12 May 2015

Symbol Identification

	Batch Code		Storage		Catalog number
	<i>In vitro</i> diagnostic medical device		Manufacturer	SN	Serial Number
	Consult instructions for use		Contains sufficient for <n> tests		Use by YYYY-MM-DD

Herceptin is a trademark of Genentech, Inc. and F. Hoffmann-La Roche Ltd.